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Moves to the “Forgotten Valve”*
Alec Vahanian, MD,yz Jean Michel Juliard, MDyzSEE PAGE 2475T ricuspid regurgitation (TR) is very frequentin the population. More than 80% of TR issecondary to left-sided heart disease that
causes right ventricular (RV) volume or pressure
overload. As an illustration, >20% of patients under-
going cardiac surgery for left-sided valvular disease
present with signiﬁcant TR (1,2).
Severe TR, either primary or secondary, is an in-
dependent predictor of poor prognosis. Both Euro-
pean and U.S. guidelines state that, in patients
undergoing left-sided cardiac surgery, intervention
on the tricuspid valve is indicated if TR is severe and
should be considered in moderate TR with annular
dilation and/or prior RV failure.
Early tricuspid surgery is at low risk. Conversely,
when TR develops or persists after mitral valve sur-
gery, reoperation carries a high risk related to cardiac
and extracardiac conditions (1–3). Thus, there is a
rationale for transcatheter treatment of the tricuspid
valve. Today, we are at the very early phase of
transcatheter tricuspid valve therapy in comparison
with >200,000 transcatheter aortic valve re-
placements and >25,000 MitraClip implantations.
The initial experience of transcatheter therapy in
patients with native TR was in compassionate use
with the implantation of valve prostheses at the
inferior and/or both superior vena cava. Self-
expandable and balloon-expandable prostheses were
used (4,5). These case reports show feasibility and
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The ﬁrst successful transcatheter tricuspid repair
for severe TR was recently performed using the
Mitralign system (Tewksbury, Massachusetts), which
enables the performance of a plication of the tricuspid
annulus reproducing the Kay operation (6,7). Ten
patients have been treated to date. The TriCinch
system (4Tech Cardio, Dublin, Ireland) comprises a
corkscrew anchored in the tricuspid annulus, a self-
expanding stent deployed in the inferior vena cava,
and a Dacron band connecting both and tensioning
the tricuspid annulus (8). To date, 8 patients have
been enrolled in an ongoing feasibility trial.The MitraClip device (Abbott Vascular, Santa Clara,
California) has been used anecdotally for the treat-
ment of secondary TR. The study by Campelo-Parada
et al. (9) in this issue of the Journal is original; the
authors report a new concept that consists in the
implantation of a Spacer, positioned at the level of
the tricuspid oriﬁce on a rail anchored in the RV apex.
The aim is to reduce TR by decreasing the regurgitant
oriﬁce. It is also the ﬁrst case series in the ﬁeld of
transcatheter tricuspid repair because it reports on 7
high-risk patients. The procedure was successful
technically and safe in all cases. At 30 days, there
were fewer signs of heart failure and better functional
status. TR was reduced from severe to moderate.
LESSONS THAT CAN BE TAKEN FROM THIS
VERY PRELIMINARY EXPERIENCE
1. Transcatheter tricuspid valve repair is feasible.
Transvenous access to the tricuspid valve, through
the jugular or femoral route, is much easier than
that to the mitral valve and allows for placement of
large devices. A transatrial approach is feasible, but
requires a thoracotomy. In contrast, a transapical
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2485approach is not feasible on the right side. The
Spacer device will probably be easier to position
than the devices described earlier. Transcatheter
valve replacement will be more challenging owing
to the large size and the nonplanar nature of the
tricuspid annulus, the absence of calciﬁcation on
the annulus and the valves, and the risk of
impeding atrioventricular conduction.
2. Echocardiography guidance will be integral as is
the case in the mitral ﬁeld even if imaging of the
TR may be more difﬁcult.
3. Safety is good, but needs to be assessed in a larger
series. With the other devices, there is a potential
risk of compromising the structures which are
in the vicinity, such as the right coronary
artery, which will require careful screening using
computed tomography.
4. A short-term clinical improvement is observed
despite the incomplete reduction in TR. This is a
signiﬁcant achievement for inoperable patients, in
whom quality of life and reduction of rehospitali-
zation and medical treatment are important.
5. The modest improvement in the degree of TR may
have several explanations. First, the Spacer, as the
other current devices, does not reproduce ring
annuloplasty, which has been shown to be superior
to stiches and Kay procedures (10). Second, pa-
tients treated in these ﬁrst-in-man studies had
irreversible enlargement of the tricuspid annulus
and severe valve tethering. In such cases, repair is
not expected to provide an effective, and certainly
not a durable, reduction of TR and replacement is
preferable. The series by Campello-Parada et al. (9)
also illustrates that measuring TR after implanta-
tion of a Spacer will be challenging. In addition,
measurement of severity of TR should be done by
transthoracic echocardiography before and later
after the procedure and not using transesophageal
echocardiography during the procedure while the
patient is under sedation because of the highly
dynamic nature of TR.
6. The effect of RV function remains to be shown,
which will be challenging. Magnetic resonance
imaging is superior to echocardiography in this
domain, but will be difﬁcult to perform in the
presence of deﬁbrillators or pacemakers. The
determination of the threshold for irreversible RV
damage where isolated intervention on TR may be
“futile” is largely unknown.7. Durability remains to be investigated. Recurrence
of TR will be a concern with all devices. In the
particular case of the Spacer, we also need to know
the long-term consequences of contact between
the device and the leaﬂets, the risk of sec-
ondary dislocation, ventricular arrhythmias, and
thrombosis.
8. The Heart Team approach will be essential to
eliminate treating patients where comorbidities
make any intervention futile. Similarly, durable
effects of any tricuspid intervention cannot be
expected if signiﬁcant left-sided heart disease is
left untreated. Finally, the Heart Team must select
the most appropriate type of intervention. In high-
risk patients, transcatheter therapy should be
compared with medical therapy and perhaps also
with minimally invasive tricuspid valve repair (11).
Transcatheter repair may be expected to be dura-
ble and effective in well-selected secondary TR or
primary TR without important leaﬂet damage but
replacement may be preferable in other cases with
secondary TR and most cases with primary TR.
In conclusion, there is a need for transcatheter
tricuspid valve intervention. The current experience
is preliminary and suggests feasibility, safety, and
short-term clinical beneﬁts. We should now follow
what has been done successfully in the ﬁeld of
transcatheter aortic valve replacement, (i.e., carefully
evaluate the results and reﬁne the technology). The
ﬁeld of application of transcatheter tricuspid valve
therapy will certainly be for high-risk or inoperable
patients. In the future, if both tricuspid and mitral
transcatheter interventions prove to be effective and
durable, they could potentially be combined in pa-
tients at lower risk in the same way as in surgery.
Finally, it may be expected that, in parallel to what is
observed in the aortic and mitral ﬁelds, the intro-
duction of tricuspid transcatheter repair will increase
patient referral with the indirect consequence of
increasing the number of operative interventions
performed (12).
Thus, a lot of work is in front of us, but now the
tricuspid valve will no longer be forgotten.
REPRINT REQUESTS AND CORRESPONDENCE: Dr.
Alec Vahanian, Cardiology Department, Bichat
Hospital, AP-HP, 46 rue Henri Huchard, 75018 Paris,
France. E-mail: alec.vahanian@aphp.fr.RE F E RENCE S1. Arsalan M, Walther T, Smith RL II,
Grayburn PA. Tricuspid regurgitation diagnosisand treatment. Eur Heart J 2015 Sep 10 [E-pub
ahead of print].2. Taramasso M, Vanermen H, Maisano F,
Guidotti A, La Canna G, Alﬁeri O. The growing
Vahanian and Juliard J A C C V O L . 6 6 , N O . 2 2 , 2 0 1 5
Transcatheter Tricuspid Valve Repair D E C E M B E R 8 , 2 0 1 5 : 2 4 8 4 – 6
2486clinical importance of secondary tricuspid regur-
gitation. J Am Coll Cardiol 2012;59:703–10.
3. Vassileva CM, Shabosky J, Boley T, Markwell S,
HazelriggS.Tricuspidvalve surgery: thepast10years
from the Nationwide Inpatient Sample (NIS) data-
base. J Thorac Cardiovasc Surg 2012;143:1043–9.
4. Lauten A, Doenst T, Hamadanchi A, Franz M,
Figulla HR. Percutaneous bicaval valve implanta-
tion for transcatheter treatment of tricuspid
regurgitation: clinical observations and 12-month
follow-up. Circ Cardiovasc Interv 2014;7:268–72.
5. Laule M, Stangl V, Sanad W, Lembcke A,
Baumann G, Stangl K. Percutaneous transfemoral
management of severe secondary tricuspid regur-
gitationwith Edwards Sapien XTbioprosthesis:ﬁrst-
in-man experience. J Am Coll Cardiol 2013;61:
1929–31.6. Schofer J, Bijuklic K, Tiburtius C, Hansen L,
Groothuis A, Hahn RT. First-in-human trans-
catheter tricuspid valve repair in a patient with
severely regurgitant tricuspid valve. J Am Coll
Cardiol 2015;65:1190–5.
7. Kay JH, Maselli-Campagna G, Tsuji KK. Surgical
treatment of tricuspid insufﬁciency. Ann Surg
1965;162:53–8.
8. Latib A, Agricola E, Pozzoli A, Denti P. First-in-
man implantation of a trisuspid annular remodel-
ing device for functional tricuspid regurgitation.
J Am Coll Cardiol Intv 2015;8:e211–4.
9. Campelo-Parada F, Perlman G, Philippon F,
et al. First-in-Man Experience of a Novel Trans-
catheter Repair System for Treating Severe
Tricuspid Regurgitation. J Am Coll Cardiol 2015;
66:2475–83.10. Navia JL, Nowicki ER, Blackstone EH, et al.
Surgical management of secondary tricuspid valve
regurgitation: annulus, commissure, or leaﬂet
procedure? J Thorac Cardiovasc Surg 2010;139:
1473–82.e5.
11. Pfanmuler B, Misfeld M, Borger MA, et al.
Isolated reoperative minimally invasive tricuspid
valve operations. Ann Thorac Surg 2012;94:
2005–10.
12. Mohr FW. Decade in review–valvular dis-
ease: current perspectives on treatment of
valvular heart disease. Nat Rev Cardiol 2014;
11:637–8.KEY WORDS interventional cardiology,
transcatheter valve, tricuspid regurgitation
